| Global prevalence and genotype distribution of hepatitis C virus infection in 2015: a modelling study S Blach, S Zeuzem, M Manns, I Altraif, AS Duberg, DH Muljono, I Waked, ... The lancet Gastroenterology & hepatology 2 (3), 161-176, 2017 | 2081 | 2017 |
| The present and future disease burden of hepatitis C virus (HCV) infection with today's treatment paradigm H Razavi, I Waked, C Sarrazin, RP Myers, R Idilman, F Calinas, W Vogel, ... Journal of viral hepatitis 21, 34-59, 2014 | 560 | 2014 |
| PAGE-B predicts the risk of developing hepatocellular carcinoma in Caucasians with chronic hepatitis B on 5-year antiviral therapy G Papatheodoridis, G Dalekos, V Sypsa, C Yurdaydin, M Buti, J Goulis, ... Journal of hepatology 64 (4), 800-806, 2016 | 445 | 2016 |
| Hepatic steatosis: quantification by proton density fat fraction with MR imaging versus liver biopsy IS Idilman, H Aniktar, R Idilman, G Kabacam, B Savas, A Elhan, A Celik, ... Radiology 267 (3), 767-775, 2013 | 422 | 2013 |
| Historical epidemiology of hepatitis C virus (HCV) in selected countries P Bruggmann, T Berg, ALH Øvrehus, C Moreno, CE Brandão Mello, ... Journal of viral hepatitis 21, 5-33, 2014 | 414 | 2014 |
| Seroprevalence of hepatitis B and C virus infections and risk factors in Turkey: a fieldwork TURHEP study N Tozun, O Ozdogan, Y Cakaloglu, R Idilman, Z Karasu, U Akarca, ... Clinical Microbiology and Infection 21 (11), 1020-1026, 2015 | 390 | 2015 |
| The risk of hepatocellular carcinoma decreases after the first 5 years of entecavir or tenofovir in Caucasians with chronic hepatitis B GV Papatheodoridis, R Idilman, GN Dalekos, M Buti, H Chi, ... Hepatology 66 (5), 1444-1453, 2017 | 308 | 2017 |
| Oral prenylation inhibition with lonafarnib in chronic hepatitis D infection: a proof-of-concept randomised, double-blind, placebo-controlled phase 2A trial C Koh, L Canini, H Dahari, X Zhao, SL Uprichard, V Haynes-Williams, ... The Lancet Infectious Diseases 15 (10), 1167-1174, 2015 | 287 | 2015 |
| Strategies to manage hepatitis C virus (HCV) disease burden H Wedemeyer, AS Duberg, M Buti, WM Rosenberg, S Frankova, G Esmat, ... Journal of viral hepatitis 21, 60-89, 2014 | 273 | 2014 |
| Adding pegylated interferon to entecavir for hepatitis B e antigen–positive chronic hepatitis B: A multicenter randomized trial (ARES study) WP Brouwer, Q Xie, MJ Sonneveld, N Zhang, Q Zhang, F Tabak, ... Hepatology 61 (5), 1512-1522, 2015 | 210 | 2015 |
| aMAP risk score predicts hepatocellular carcinoma development in patients with chronic hepatitis R Fan, G Papatheodoridis, J Sun, H Innes, H Toyoda, Q Xie, S Mo, ... Journal of Hepatology 73 (6), 1368-1378, 2020 | 207 | 2020 |
| Natural history and treatment of chronic delta hepatitis C Yurdaydın, R Idilman, H Bozkaya, AM Bozdayi Journal of viral hepatitis 17 (11), 749-756, 2010 | 207 | 2010 |
| A comparison of liver fat content as determined by magnetic resonance imaging-proton density fat fraction and MRS versus liver histology in non-alcoholic fatty liver disease IS Idilman, O Keskin, A Celik, B Savas, A Halil Elhan, R Idilman, ... Acta radiologica 57 (3), 271-278, 2016 | 187 | 2016 |
| Incidence and predictors of hepatocellular carcinoma in Caucasian chronic hepatitis B patients receiving entecavir or tenofovir GV Papatheodoridis, GN Dalekos, C Yurdaydin, M Buti, J Goulis, ... Journal of hepatology 62 (2), 363-370, 2015 | 179 | 2015 |
| Peginterferon alfa-2a plus tenofovir disoproxil fumarate for hepatitis D (HIDIT-II): a randomised, placebo controlled, phase 2 trial H Wedemeyer, C Yurdaydin, S Hardtke, FA Caruntu, MG Curescu, ... The Lancet infectious diseases 19 (3), 275-286, 2019 | 171 | 2019 |
| Global multi-stakeholder endorsement of the MAFLD definition N Méndez-Sánchez, E Bugianesi, RG Gish, F Lammert, H Tilg, ... The lancet Gastroenterology & hepatology 7 (5), 388-390, 2022 | 166 | 2022 |
| Pathogenesis of hepatitis B and C‐induced hepatocellular carcinoma R Idilman, N De Maria, A Colantoni, DH Van Thiel Journal of viral hepatitis 5 (5), 285-299, 1998 | 164 | 1998 |
| Optimizing lonafarnib treatment for the management of chronic delta hepatitis: the LOWR HDV‐1 study C Yurdaydin, O Keskin, Ç Kalkan, F Karakaya, A Çalişkan, E Karatayli, ... Hepatology 67 (4), 1224-1236, 2018 | 154 | 2018 |
| Clinical trial: insulin‐sensitizing agents may reduce consequences of insulin resistance in individuals with non‐alcoholic steatohepatitis R Idilman, D Mizrak, D Corapcioglu, M Bektas, B Doganay, M Sayki, ... Alimentary pharmacology & therapeutics 28 (2), 200-208, 2008 | 153 | 2008 |
| The impact of previous HBV infection on the course of chronic hepatitis C N De Maria, A Colantoni, L Friedlander, G Leandro, R Idilman, J Harig, ... Official journal of the American College of Gastroenterology| ACG 95 (12 …, 2000 | 142 | 2000 |
